2. UroToday Home
  3. Categories

Upper Tract Tumors

Comparative Analysis of Long-Term Renal Outcomes in Upper Tract Urothelial Carcinoma: Local Ablation Versus Radical Nephroureterectomy.

(1) Background: Upper tract urothelial carcinoma (UTUC) is typically managed through radical nephroureterectomy (RNU) or local ablation (LA). Compared to RNU, LA offers nephron-sparing benefit for select patients but may present increased recurrence risk.

Development and validation of a predictive model for postoperative metastasis of upper tract urothelial carcinoma after radical nephroureterectomy and analysis of risk factors for different metastatic sites: a multicenter study.

To develop a prediction model for assessing the risk of postoperative metastasis in upper tract urothelial carcinoma (UTUC) patients after radical nephroureterectomy (RNU) and to analyze independent risk factors for metastasis at different sites.

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update.

We present a summary of the 2025 update for the European Association of Urology (EAU) guidelines for upper urinary tract urothelial carcinoma (UTUC). The aim is to provide practical recommendations on the clinical management of UTUC with a focus on diagnosis, treatment, and follow-up.

Bladder cuff excision at radical nephroureterectomy improved survival in upper tract urothelial carcinoma.

To test for survival differences after radical nephroureterectomy (RNU) in pT1-T3N0 upper tract urothelial carcinoma (UTUC) patients according to bladder cuff excision (BCE) status.

Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified RNU patients and documented BCE status.

Geriatric Nutritional Risk Index as a prognostic marker for predicting survival outcomes in patients with UTUC after radical nephroureterectomy.

The purpose of this study was to determine the prognostic value of the Geriatric Nutritional Risk Index (GNRI) in patients with upper tract urothelial carcinoma (UTUC) after radical nephrectomy (RNU).

Long term survival in elderly patients with resectable upper tract urothelial carcinoma: analysis of hospital-based cancer registry data in Japan.

To clarify the long-term prognoses of elderly upper tract urothelial carcinoma (UTUC) patients after surgery.

We used a hospital-based cancer registry data in Japan to extract patients with pT1-3N0M0 UTUC diagnosed in 2009 who underwent surgery, and classified them by age group (≤ 64, 65-74, ≥ 75 years old).

The role of surgical resection of the primary tumor in metastatic upper tract urothelial carcinoma: a systematic review and meta-analysis.

To evaluate the role of extirpative surgery for the primary tumor in metastatic upper tract urothelial carcinoma (mUTUC).

The PubMed, Web of Science, and Cochrane Library were searched on July 2024 to identify relevant studies according to the Preferred Reporting Items for Systematic Review (PRISMA) statement.

Non-Caucasian Race/Ethnicity Predisposes to Unfavorable Stage and Grade at Upper Tract Urothelial Carcinoma Diagnosis - Beyond the Abstract

Historical non-Caucasian upper tract urothelial carcinoma (UTUC) patients appeared to harbor less favorable stage and grade at presentation. This unfortunate condition may be justified by lower access to care. However, despite the improvements in health policy that guarantee a higher and an equal access to treatment, it could be possible that historical discrepancies may be eliminated.

Risk-adapted scoring model to identify candidates benefiting from adjuvant chemotherapy after radical nephroureterectomy for localized upper urinary tract urothelial carcinoma: A multicenter study.

Adjuvant chemotherapy (AC) is recommended for muscle-invasive or lymph node-positive upper urinary tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). However, disease recurrences are frequently observed in pT1 disease, and AC may increase the risk of overtreatment in pT2 UTUC patients.

Efficacy and safety of dose-dense gemcitabine and cisplatin as neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma (cT2-3N0M0).

Neoadjuvant chemotherapy for upper tract urothelial carcinoma has shown favorable results. However, few studies have been conducted on dose-dense regimens that have demonstrated superior efficacy in bladder cancer.

Page 1 of 123